Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM
Daniel Tewkesbury, Andrew Jones, R.J. Bright-Thomas, Alyn Cratchley, Karen Piper Hanley, Judith I. Wyatt, Varinder Athwal, Peter Barry
Topics & Concepts
IvacaftorMedicineCystic fibrosisCohortEtiologyInternal medicinePharmacotherapyPathologyGastroenterologyCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesGenetic and Kidney Cyst DiseasesBiological Research and Disease Studies